Tempest Therapeutics Stock Target Price
| TPST Stock | USD 3.20 0.01 0.31% |
Tempest Therapeutics' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Tempest Stock price.
Tempest | Target Price | Build AI portfolio with Tempest Stock |
Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
| All Next | Launch Module |
Tempest Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tempest Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tempest Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Tempest Fundamentals
| Return On Equity | -4.05 | ||||
| Return On Asset | -0.89 | ||||
| Current Valuation | 16.66 M | ||||
| Shares Outstanding | 4.93 M | ||||
| Shares Owned By Insiders | 0.09 % | ||||
| Shares Owned By Institutions | 11.80 % | ||||
| Number Of Shares Shorted | 153.64 K | ||||
| Price To Earning | 0.23 X | ||||
| Price To Book | 2.48 X | ||||
| EBITDA | (40.14 M) | ||||
| Net Income | (41.84 M) | ||||
| Cash And Equivalents | 51.62 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 15.37 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 3.05 X | ||||
| Book Value Per Share | 1.43 X | ||||
| Cash Flow From Operations | (33.03 M) | ||||
| Short Ratio | 3.93 X | ||||
| Earnings Per Share | (9.73) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 24 | ||||
| Beta | -2.33 | ||||
| Market Capitalization | 15.77 M | ||||
| Total Asset | 41.49 M | ||||
| Retained Earnings | (207.11 M) | ||||
| Working Capital | 17.25 M | ||||
| Net Asset | 41.49 M |
About Tempest Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tempest Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tempest Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tempest Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.